Hansa Biopharma AB (publ) / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €430.47M +102.3% €299.36M +214.3% 69.5% +0.25 pp N/A N/A
    (estimated) €212.74M +125.3% €95.26M +5,003.5% 44.8% +0.43 pp N/A N/A
    (estimated) €94.42M +117.8% €1.87M -105.6% 2.0% +0.79 pp €13.54M -132.9% 14.3% +1.1 pp
    (estimated) €43.35M +69.3% -€33.46M -15.4% -77.2% +0.77 pp -€41.15M +2.4% -94.9% +0.62 pp
    (estimated) €25.60M +63.4% -€39.56M -46.4% -154.5% +3.2 pp -€40.19M -34.9% -157.0% +2.4 pp
    €15.67M +27.8% -€73.83M -2.9% -471.2% +1.5 pp -€61.71M -10.7% -393.9% +1.7 pp
    €12.26M -13.2% -€76.06M +36.1% -620.3% -2.2 pp -€69.08M +51.3% -563.3% -2.4 pp
    €14.13M +356.1% -€55.89M +11.5% -395.5% +12 pp -€45.67M +4.3% -323.2% +11 pp
    €3.10M +455.6% -€50.14M +30.3% -1,618.4% +53 pp -€43.79M +65.1% -1,413.2% +33 pp
    €557.68K +81.3% -€38.49M +16.9% -6,901.5% +38 pp -€26.52M -12.5% -4,755.3% +51 pp
    €307.65K +0.2% -€32.92M +45.2% -10,701.8% -33 pp -€30.30M +64.0% -9,849.8% -38 pp
    €307.10K -2.4% -€22.68M +40.4% -7,384.6% -23 pp -€18.48M +36.8% -6,017.5% -17 pp
    €314.78K +33.5% -€16.16M +59.0% -5,132.5% -8.2 pp -€13.51M +57.8% -4,291.0% -6.6 pp
    €235.86K -52.5% -€10.16M +67.7% -4,309.0% -31 pp -€8.56M +65.7% -3,628.5% -26 pp
    €496.96K +15.2% -€6.06M +128.2% -1,219.5% -6.0 pp -€5.17M +151.9% -1,039.4% -5.6 pp
    €431.30K +173.1% -€2.66M +65.4% -615.8% +4.0 pp -€2.05M +51.5% -475.4% +3.8 pp
    €157.94K -34.1% -€1.61M +6.7% -1,016.9% -3.9 pp -€1.35M -17.4% -857.0% -1.7 pp
    €239.50K +104.2% -€1.51M -33.0% -628.8% +13 pp -€1.64M -33.9% -684.5% +14 pp
    €117.26K -71.2% -€2.25M +30.4% -1,916.4% -15 pp -€2.48M +50.0% -2,116.6% -17 pp
    €406.80K +49.1% -€1.72M +19.2% -423.6% +1.1 pp -€1.65M +31.3% -406.8% +0.55 pp
    €272.88K +2,778.0% -€1.45M +518.1% -529.9% +19 pp -€1.26M +18.4% -461.8% +110 pp
    €9.48K -€233.96K -2,467.5% -€1.06M -11,228.5%

    Notifications